teal triangle graphic

R&D Pipeline

R&D Pipeline

Pipeline of Key Proprietary Product Candidates

We have a pipeline of product candidates in development for psychiatric and neurological disorders.

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Olanzapine and samidorphan

    • Schizophrenia and Bipolar I Disorder (Pediatric)

      Phase 3

    Overview

    Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.

    Clinical Trials

    Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.

  • ALKS 2680

    • Narcolepsy Type 1

      Phase 2

    • Narcolepsy Type 2

      Phase 1

    Overview

    ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.

    Clinical Trials

    ALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950.

    ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

  • Orexin Agonists

    • Neuroscience Indications

      Discovery

    Overview

    Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.

Last updated: April 2024